Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D

Zoledronic acid (Zol) is a widely used intravenous aminobisphosphonate to treat both benign and malignant skeletal diseases, and bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious side effect whose pathophysiology remains poorly understood. Vascular Endothelial Growth Factor (VEGF)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Federica Bellone, Antonino Catalano, Angelo Ruggero Sottile, Agostino Gaudio, Saverio Loddo, Francesco Corica, Nunziata Morabito
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	bisphosphonate zoledronic acid vascular endothelial growth factor osteonecrosis postmenopausal osteoporosis Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/43f5e892991a4794981d523cad9a41e4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:43f5e892991a4794981d523cad9a41e4
record_format	dspace
spelling	oai:doaj.org-article:43f5e892991a4794981d523cad9a41e42021-11-18T06:08:36ZEarly Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D2296-858X10.3389/fmed.2021.748438https://doaj.org/article/43f5e892991a4794981d523cad9a41e42021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmed.2021.748438/fullhttps://doaj.org/toc/2296-858XZoledronic acid (Zol) is a widely used intravenous aminobisphosphonate to treat both benign and malignant skeletal diseases, and bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious side effect whose pathophysiology remains poorly understood. Vascular Endothelial Growth Factor (VEGF) has been recognized to mediate BRONJ in cancer patients undergoing Zol treatment, however data on VEGF are lacking in patients with osteoporosis. Increasing evidences demonstrate that vitamin D influences VEGF levels. The aim of this study was to investigate the influence of Zol on VEGF levels and the possible role for vitamin D on the Zol mediated changes of VEGF concentration in women with postmenopausal osteoporosis. Twenty-eight postmenopausal women with osteoporosis were enrolled and randomized into two groups to receive Zol (5 mg) or placebo. At baseline, at day-3 and day-30 VEGF serum levels were measured; bone turnover markers, 25-hydroxyvitamin D [25(OH)D] and serum calcium were evaluated at baseline. In Zol-treated women, VEGF increased significantly on day-3, and then decreased on day-30. In the Zol-treated women, the percent change of VEGF levels between baseline and day-30 (−18% at day-30 vs. baseline, p = 0.01) was significantly associated with serum 25(OH)D values (r = 0.29, p = 0.028). At a stepwise multiple regression analysis, after correcting for age, BMI, time since menopause, femoral neck BMD, osteocalcin, C-terminal telopeptide of type 1 collagen, and baseline VEGF levels, 25(OH)D levels were independently associated with VEGF change (β = 1.7, SE = 0.71, p = 0.03). For the first time, we detected early modifications of circulating VEGF in postmenopausal women receiving Zol for osteoporosis, identifying a vitamin D-dependent modulation of these changes.Federica BelloneAntonino CatalanoAngelo Ruggero SottileAgostino GaudioSaverio LoddoFrancesco CoricaNunziata MorabitoFrontiers Media S.A.articlebisphosphonatezoledronic acidvascular endothelial growth factorosteonecrosispostmenopausalosteoporosisMedicine (General)R5-920ENFrontiers in Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	bisphosphonate zoledronic acid vascular endothelial growth factor osteonecrosis postmenopausal osteoporosis Medicine (General) R5-920
spellingShingle	bisphosphonate zoledronic acid vascular endothelial growth factor osteonecrosis postmenopausal osteoporosis Medicine (General) R5-920 Federica Bellone Antonino Catalano Angelo Ruggero Sottile Agostino Gaudio Saverio Loddo Francesco Corica Nunziata Morabito Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D
description	Zoledronic acid (Zol) is a widely used intravenous aminobisphosphonate to treat both benign and malignant skeletal diseases, and bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious side effect whose pathophysiology remains poorly understood. Vascular Endothelial Growth Factor (VEGF) has been recognized to mediate BRONJ in cancer patients undergoing Zol treatment, however data on VEGF are lacking in patients with osteoporosis. Increasing evidences demonstrate that vitamin D influences VEGF levels. The aim of this study was to investigate the influence of Zol on VEGF levels and the possible role for vitamin D on the Zol mediated changes of VEGF concentration in women with postmenopausal osteoporosis. Twenty-eight postmenopausal women with osteoporosis were enrolled and randomized into two groups to receive Zol (5 mg) or placebo. At baseline, at day-3 and day-30 VEGF serum levels were measured; bone turnover markers, 25-hydroxyvitamin D [25(OH)D] and serum calcium were evaluated at baseline. In Zol-treated women, VEGF increased significantly on day-3, and then decreased on day-30. In the Zol-treated women, the percent change of VEGF levels between baseline and day-30 (−18% at day-30 vs. baseline, p = 0.01) was significantly associated with serum 25(OH)D values (r = 0.29, p = 0.028). At a stepwise multiple regression analysis, after correcting for age, BMI, time since menopause, femoral neck BMD, osteocalcin, C-terminal telopeptide of type 1 collagen, and baseline VEGF levels, 25(OH)D levels were independently associated with VEGF change (β = 1.7, SE = 0.71, p = 0.03). For the first time, we detected early modifications of circulating VEGF in postmenopausal women receiving Zol for osteoporosis, identifying a vitamin D-dependent modulation of these changes.
format	article
author	Federica Bellone Antonino Catalano Angelo Ruggero Sottile Agostino Gaudio Saverio Loddo Francesco Corica Nunziata Morabito
author_facet	Federica Bellone Antonino Catalano Angelo Ruggero Sottile Agostino Gaudio Saverio Loddo Francesco Corica Nunziata Morabito
author_sort	Federica Bellone
title	Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D
title_short	Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D
title_full	Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D
title_fullStr	Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D
title_full_unstemmed	Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D
title_sort	early changes of vegf levels after zoledronic acid in women with postmenopausal osteoporosis: a potential role of vitamin d
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/43f5e892991a4794981d523cad9a41e4
work_keys_str_mv	AT federicabellone earlychangesofvegflevelsafterzoledronicacidinwomenwithpostmenopausalosteoporosisapotentialroleofvitamind AT antoninocatalano earlychangesofvegflevelsafterzoledronicacidinwomenwithpostmenopausalosteoporosisapotentialroleofvitamind AT angeloruggerosottile earlychangesofvegflevelsafterzoledronicacidinwomenwithpostmenopausalosteoporosisapotentialroleofvitamind AT agostinogaudio earlychangesofvegflevelsafterzoledronicacidinwomenwithpostmenopausalosteoporosisapotentialroleofvitamind AT saverioloddo earlychangesofvegflevelsafterzoledronicacidinwomenwithpostmenopausalosteoporosisapotentialroleofvitamind AT francescocorica earlychangesofvegflevelsafterzoledronicacidinwomenwithpostmenopausalosteoporosisapotentialroleofvitamind AT nunziatamorabito earlychangesofvegflevelsafterzoledronicacidinwomenwithpostmenopausalosteoporosisapotentialroleofvitamind
_version_	1718424532746764288

Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D

Ejemplares similares